{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', '3.', 'ABBREVIATIONS AND DEFINITIONS', 'Term', 'Definition', '6MWT', '6-Minute Walk Test', 'ADE', 'Adverse device effect', 'AE', 'Adverse event', 'ALT', 'Alanine aminotransferase', 'AST', 'Aspartate aminotransferase', 'ATP', 'Adenosine triphosphate', 'AUC', 'Area under the plasma concentration versus time curve', 'AUC0-t', 'Area under the plasma concentration VS time curve from time 0 to end of the', 'dosing interval', 'AUC0-inf', 'Area under the plasma concentration curve from baseline to infinity', 'AUC0-24', 'Area under the plasma concentration curve from baseline to 24 hours postdose', 'BMI', 'Body mass index', 'CIOMS', 'Council for International Organizations of Medical Sciences', 'CGI', 'Clinician Global Impression Scales', 'Cmax', 'Maximum plasma concentration', 'C-SSRS', 'Columbia-Suicide Severity Rating Scale', 'EC', 'Ethics Committee', 'ECG', 'Electrocardiogram', 'eCRF', 'Electronic Case Report Form', 'EDC', 'Electronic data capture', 'ETC', 'Electron Transport Chain', 'GCP', 'Good Clinical Practice', 'IB', \"Investigator's Brochure\", 'ICF', 'Informed consent form', 'ICH', 'International Conference on Harmonisation of Technical Requirements for', 'Registration of Pharmaceuticals for Human Use', 'IFU', 'Instructions for Use', 'IMM', 'Inner mitochondrial membrane', 'IMP', 'Investigational medicinal product', 'ISR', 'Injection site reaction', 'IV', 'Intravenous', 'ITT', 'Intention-to-treat', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'MFD', 'Maximum feasible dose', 'mL', 'Milliliter', 'MTP-131', 'Elamipretide, SS-31, SBT-031, or BendaviaTM', 'mtDNA', 'Mitochondrial DNA', 'nDNA', 'Nuclear DNA', 'PK', 'Pharmacokinetic(s)', 'PGI', 'Patient Global Impression Scales', 'PMMSA', 'Primary Mitochondrial Myopathy Symptom Assessment', 'PT', 'Preferred term', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '20']['SPIMM-301 Version 4.0', '15 June 2018', 'Term', 'Definition', 'RA', 'Risk assessment', 'ROS', 'Reactive oxygen species', 'SADE', 'Serious adverse device effect', 'SAE', 'Serious adverse event', 'SAP', 'Statistical Analysis Plan', 'SC', 'Subcutaneous', 'SMP', 'Safety Management Plan', 'SOC', 'System organ class', 'SUSAR', 'Suspected unexpected serious adverse reaction', 'TEADE', 'Treatment-emergent adverse device effect', 'TEAE', 'Treatment-emergent adverse event', 'ULN', 'Upper limit of normal', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '21']['SPIMM-301 Version 4.0', '15 June 2018', '4.', 'INTRODUCTION', 'This pivotal trial will be conducted in strict accordance with the current versions of the Council', 'for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines,', 'ICH GCP guidelines, the Declaration of Helsinki, and all applicable laws and regulations. For', 'detailed information on the elamipretide delivery system and the nonclinical and clinical studies', \"conducted to date, please refer to the most recent edition of the elamipretide Investigator's\", 'Brochure (IB).', '4.1.', 'Primary Mitochondrial Myopathy (PMM)', '4.1.1.', 'Background', 'The National Organization for Rare Disorders (NORD) Physician Guide to Mitochondrial', 'Myopathies describes PMM as genetic disorders of the mitochondrial respiratory chain affecting', 'predominantly, but not exclusively, skeletal muscle (Mancuso 2016). In PMM, there is an', 'exaggerated response to physical exercise due to skeletal muscle respiratory chain dysfunction.', 'The increased oxygen available during physical activity in the arterial bloodstream cannot be', 'effectively utilized in PMM subjects by the skeletal muscle cells and as a result leads to', 'debilitating muscle weakness, muscle atrophy, limited exercise capacity, and symptoms of', 'fatigue. The severity of PMM is variable but the progressive reduction in muscle strength and', 'exercise capacity eventually significantly compromises the ability to perform activities of daily', 'living (DiMauro 2004; Pfeffer 2013; Tarnopolsky 2004).', '4.1.2.', 'Etiology', 'Mitochondria are cellular organelles with an inner and an outer membrane and a matrix', 'containing mitochondrial DNA (mtDNA). Mitochondria host multiple metabolic pathways', 'required for normal cellular function. Mitochondrial function is under the dual control of genes', 'within mtDNA as well as within nuclear DNA (nDNA). PMM is caused by mutations in nDNA', 'and/or mtDNA which result in electron transport chain (ETC) dysfunction and a corresponding', 'reduction in oxidative phosphorylation and production of ATP (Chinnery 2014; DiMauro 2003).', 'Mutations causing PMM are subclassified as follows (DiMauro 2003):', 'Disorders involving mtDNA mutations that impair mitochondrial protein synthesis in', 'toto', 'Disorders involving mtDNA mutations that affect the subunits of the respiratory', 'chain', 'Disorders involving nDNA mutations in genes encoding subunits or ancillary proteins', 'of the respiratory chain', 'Disorders involving nDNA mutations causing defects of intergenomic signaling', 'Disorders involving nDNA mutations causing defects of mitochondrial protein', 'importation', 'Disorders involving nDNA mutations causing alterations of the lipid milieu of the', 'inner mitochondrial membrane', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '22']\n\n###\n\n", "completion": "END"}